Eloxx Pharmaceuticals, Inc. (ELOX)
ELOX Stock Price Chart
Explore Eloxx Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ELOX price movements and trends.
ELOX Company Profile
Discover essential business fundamentals and corporate details for Eloxx Pharmaceuticals, Inc. (ELOX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Jun 2026
Employees
10.00
Website
https://www.eloxxpharma.comCEO
Sumit Aggarwal
Description
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
ELOX Financial Timeline
Browse a chronological timeline of Eloxx Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$6.40.
Upcoming earnings on 10 Aug 2026
Stock split effective on 1 Jun 2026
Shares were split 1 : 11 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 May 2026
EPS came in at -$0.88 surpassing the estimated -$6.40 by +86.25%.
Earnings released on 25 Feb 2026
Earnings released on 17 Apr 2025
EPS came in at -$4.95 .
Earnings released on 13 Mar 2025
Earnings released on 16 Dec 2024
Earnings released on 17 Jun 2024
Earnings released on 10 Jun 2024
Earnings released on 13 Nov 2023
EPS came in at -$14.41 falling short of the estimated -$1.97 by -631.47%.
Earnings released on 14 Aug 2023
EPS came in at -$21.56 falling short of the estimated -$1.54 by -1.30k%.
Earnings released on 15 May 2023
EPS came in at -$31.68 falling short of the estimated -$2.55 by -1.14k%.
Earnings released on 3 Apr 2023
EPS came in at -$32.12 falling short of the estimated -$2.97 by -981.48%.
Stock split effective on 2 Dec 2022
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$3.60 surpassing the estimated -$4.40 by +18.18%.
Earnings released on 15 Aug 2022
EPS came in at -$52.81 falling short of the estimated -$44.00 by -20.02%.
Earnings released on 6 May 2022
EPS came in at -$57.21 falling short of the estimated -$39.60 by -44.47%.
Earnings released on 31 Mar 2022
EPS came in at -$61.61 falling short of the estimated -$52.81 by -16.66%.
Earnings released on 9 Nov 2021
EPS came in at -$48.40 surpassing the estimated -$61.61 by +21.44%.
Earnings released on 16 Aug 2021
EPS came in at -$88.01 falling short of the estimated -$57.21 by -53.84%.
ELOX Stock Performance
Access detailed ELOX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
